Tim Harris, PhD, DSc, is a scientist and business leader with 40 years of experience guiding and leading programs and researchers in a range of molecular research areas.
Currently, Dr. Harris is a venture partner at SV Health Investors where he identifies and analyzes investment opportunities. He also serves as Executive Vice President of Research and Development for Bioverativ. Dr. Harris has held the roles of Senior Vice President, Precision Medicine, and Senior Vice President, Translational Medicine and Biochemistry at Biogen, where he was responsible for establishing foundational innovative technologies that advanced research and development efforts. Previously, as Chief Technology Officer at SAIC-Frederick (now Leidos) which operates the Frederick National Laboratory, the National Cancer Institute’s leading center for cancer and AIDS research, Dr. Harris led a team of approximately 600 researchers devoted to advanced technologies spanning basic research to applied animal science. He also served as President and Chief Executive Officer of SGX Pharmaceuticals, (acquired by Eli Lilly), among other roles throughout his extensive career in the biotechnology industry.
Dr. Harris is credited with more than 100 publications and has five issued patents. He is currently on the Board of Directors of Opgen (NASDAQ: OPGN) and is a visiting professor at Columbia University.
Dr. Harris received his Bachelor of Science and doctorate degrees from the University of Birmingham in England.